Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...
TipRanks on MSN
Bank of America says market isn’t pricing in Eli Lilly’s (LLY) weight-loss drug dominance
Orforglipron is Eli Lilly’s weight-loss pill, and Bank of America expects it to enter the market in the second half of 2026 ...
President Donald Trump just announced deals with drugmakers Eli Lilly and Novo Nordisk that will yield lower prices for GLP-1 ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...
Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...
Eli Lilly said Monday that it's reducing the price of its popular weight-loss drug Zepbound on its LillyDirect platform, about a month after striking a deal with the Trump administration to lower drug ...
Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...
Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's ...
Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...
Eli Lilly and Novo Nordisk will lower prices for GLP-1 receptor agonists, aligning with the Most Favored Nation executive order to address US drug pricing disparities. Novo Nordisk's semaglutide ...
Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback